Clearly positioned among the world's leading biotechnology companies, MedImmune
has leveraged its own organic growth, and has also expanded through the key
acquisitions of U.S. Bioscience in 1999 and Aviron in 2002, as well as the
integration with Cambridge Antibody Technology and the strategic alignment with
our new parent company, AstraZeneca, in 2007. Our rapid expansion is also
attributable to the activities of our business development department,
responsible for actions such as strategic in-licensing, and to the launch of
MedImmune Ventures Inc., a wholly-owned capital venture fund.